SCHEMBL623770

SCHEMBL623770

CC(C)COc1cc(N2CCN(C(=O)c3cc(C4CC4)n(C)n3)CC2)ncn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 1/20 0.38
PSMB9 P28065 1/20 0.38
TRPC6 Q9Y210 2/20 0.36
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
ALDH1A1 P00352 1/20 0.34
ACACB O00763 6/20 0.34
PDE2A O00408 1/20 0.33
MEN1 O00255 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
NR2E1 Q9Y466 1/20 0.33
LRRK2 Q5S007 1/20 0.33
CHRM4 P08173 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
TACR2 P21452 1/20 0.32
TACR1 P25103 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL624384 0.85 MEN1 (0.34) TRPC6ALDH1A1ACACBMEN1HPGD
SCHEMBL623711 0.83 PKM (0.41) ALDH1A1ACACBMEN1HPGDKMT2A
SCHEMBL623290 0.83 PSMB8 (0.40) PSMB8PSMB9TRPC6PDK1PDK2
SCHEMBL624199 0.81 CYP1A2 (0.48) ALDH1A1PDE2AHPGDNR2E1CYP1A2
SCHEMBL624142 0.79 ALDH1A1 (0.60) ALDH1A1MEN1HPGDKMT2ACHRM4
SCHEMBL624504 0.78 CYP2C19 (0.45) TRPC6HPGDCYP1A2CYP3A4CYP2D6
SCHEMBL623300 0.76 ITGB2 (0.37) ALDH1A1ACACBMEN1HPGDKMT2A
SCHEMBL624228 0.76 HTR2A (0.49) ALDH1A1KMT2ANR2E1
SCHEMBL623267 0.76 KCNK3 (0.43) ALDH1A1MEN1HPGDKMT2ACYP2C19
SCHEMBL623188 0.76 KCNT1 (0.40) ALDH1A1ACACBMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G PSMB8 1601/4885PSMB9 1816/4885TRPC6 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.